Gout Therapeutics Market by Product Type and Disease Condition - Global Industry Analysis and Forecast to 2025

2018-05-30 / 3800.00 / Pharma & Healthcare / 107 Pages

Description

Industry Trend Analysis

The global gout therapeutics market is estimated to be around $8 billion by 2025. This market has witnessed tremendous growth in last few years due to preface of various regenerative drugs and escalated acceptance of these biologics for treatment. This can be attributed to their capability to generate potent anti-inflammatory action which speeds up treatment time. Furthermore, many other drugs are currently under clinical trials which are likely to be launched in coming years which will play an important role in the market growth. Rising incidence of gout due to changes in lifestyle, growing alcohol consumption, increasing obesity and ingestion of some specific medications will drive the growth of this market. However, binding regulations and patent expiry of leading drugs will slow down the growth of global market.

Product Outlook and Trend Analysis

Non-steroidal anti-inflammatory drugs (NSAIDs) dominates the global market because of superior level of penetration of drug, lower cost, easy availability, and ability to ease pain faster as compared to other available drugs for gout attacks. Urate lowering agents sector is expected to grow at most prominent rate during forecast period. Increasing adoption and innovation of new drugs is likely to enhance market growth. Colchicines occupies significant share in global market, due to their ability to slow down severe inflammatory response by blocking actions of neutrophils responsible for gout attacks. In 2009, FDA approved use of Colchicines for treating gout related fevers.

Regional Outlook and Trend Analysis

In 2016, the global market was dominated by North America, which can be attributed to various factors such as presence of local primary players, extensive use of gout therapies, and easily availability. U.S. dominated the regional market in 2016, followed by Canada. It is likely to sustain its leading position in the global market during the forecast period, owing to expected launch of new drugs and urate-lowering drugs. In Europe, France and Germany hold highest share for gout disease treatment drugs. Asia-Pacific is projected to witness highest growth rate due to rising incidence of gout disease, increased investments in research for the development of new and alternate therapies. Furthermore, increasing consumption of alcohol and cigarettes, changing life style, and increase in obesity rates is likely to improve growth of gout therapeutics market.

Competitive Insights

Numerous multinational as well as local players dominate the global market. Major players comprise GlaxoSmithKline plc; Merck& Co. Inc.; AstraZeneca plc; Teijin Pharma Ltd.; Novartis AG; Takeda Pharmaceutical Company Ltd.; Savient Pharmaceuticals; and Regeneron Pharmaceuticals. Development of new and innovative products, collaborations and strategic acquisitions are some of the strategies acquired by market players to have competitive advantage over their rivals.

Market Opportunities

Major players in market are shifting their focus towards more serious gout cases in order to meet unmet medical needs of drugs for effective treatments. NSAIDs and Colchicines are expected to attract large investment due to their increasing adoption and success rate in treating acute as well as chronic gout disease. Many players have collaborated for research and development to develop more efficient drug for the treatment of gout diseases. The market will be dominated by urate lowering agents that has ability to prevent gout disease by blocking genes responsible for gout disease. With FDA approval of Zurampic (in 2015) to reduce uric acid level in blood and other new drugs in clinical trials will bring in huge opportunities for key players in the market.

Gout therapeutic market is segmented as follows –

By Product Type:


Colchicines
Corticosteroids
NSAIDs
Urate-lowering Agents


By Disease Condition:


Acute Gout
Chronic Gout


By Region:

· North America


U.S
Canada
Mexico


· Europe


Germany
France
UK
Italy
Spain
Rest of Europe


· Asia-Pacific


Japan
China
Australia
India
South Korea
Rest of Asia-Pacific


· Rest of the World


Brazil
South Africa
Saudi Arabia
Turkey
United Arab Emirates
Others


Some of the key questions answered by the report are:


What was the market size in 2016 and forecast from 2017 to 2025`
What will be the industry market growth from 2017 to 2025`
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast`
What are the major segments leading the market growth and why`
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition`

Table of Content

Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Share Analysis
3.3. Market Dynamics
3.3.1. Drivers
3.3.1.1. Rising incidences of gout disease
3.3.1.2. Increase alcohol consumption
3.3.1.3. Rise in obesity
3.3.1.4. Consumption of other medication
3.3.2. Restraints
3.3.2.1. Binding regulations
3.3.2.2. Patent expiry of leading drugs
3.3.3. Opportunities
3.3.3.1. Emerging market to offer lucrative growth opportunities
3.4. Industry Trends
4. Gout Therapeutics Market, By Product Type
4.1. Introduction
4.2. Gout Therapeutics MarketAssessment and Forecast, By Product Type, 2016-2025
4.3. NSAIDs
4.3.1. Market Assessment and Forecast, By Region, 2016-2025 ($Million)
4.4. Corticosteroids
4.4.1. Market Assessment and Forecast, By Region, 2016-2025 ($Million)
4.5. Colchicine
4.5.1. Market Assessment and Forecast, By Region, 2016-2025 ($Million)
4.6. Urate-lowering agents
4.6.1. Market Assessment and Forecast, By Region, 2016-2025 ($Million)
5. Gout Therapeutics Market, By Disease Condition
5.1. Introduction
5.2. Gout Therapeutics MarketAssessment and Forecast, By Disease Condition,2016-2025
5.3. Chronic Gout
5.3.1. Market Assessment and Forecast, By Region, 2016-2025 ($Million)
5.3.2. Acute Gout
5.3.2.1. Market Assessment and Forecast, By Region, 2016-2025 ($Million)
6. Gout Therapeutics Market, By Region
6.1. Introduction
6.2. Gout Therapeutics MarketAssessment and Forecast, By Region, 2016-2025 ($Million)
6.3. North America
6.3.1. Market Assessment and Forecast, By Country, 2016-2025 ($Million)
6.3.2. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.3.3. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.3.3.1. U.S.
6.3.3.1.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.3.3.1.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.3.3.2. Canada
6.3.3.2.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.3.3.2.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.3.3.3. Mexico
6.3.3.3.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.3.3.3.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.4. Europe
6.4.1. Market Assessment and Forecast, By Country, 2016-2025 ($Million)
6.4.2. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.4.3. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.4.3.1. Germany
6.4.3.1.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.4.3.1.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.4.3.2. France
6.4.3.2.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.4.3.2.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.4.3.3. UK
6.4.3.3.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.4.3.3.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.4.3.4. Italy
6.4.3.4.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.4.3.4.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.4.3.5. Spain
6.4.3.5.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.4.3.5.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.4.3.6. Russia
6.4.3.6.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.4.3.6.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.4.3.7. Rest of Europe
6.4.3.7.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.4.3.7.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.5. Asia-Pacific
6.5.1. Market Assessment and Forecast, By Country, 2016-2025 ($Million)
6.5.2. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.5.3. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.5.3.1. Japan
6.5.3.1.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.5.3.1.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.5.3.2. China
6.5.3.2.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.5.3.2.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.5.3.3. Australia
6.5.3.3.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.5.3.3.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.5.3.4. India
6.5.3.4.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.5.3.4.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.5.3.5. South Korea
6.5.3.5.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.5.3.5.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.5.3.6. Taiwan
6.5.3.6.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.5.3.6.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.5.3.7. Rest of Asia-Pacific
6.5.3.7.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.5.3.7.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.6. Rest of the World
6.6.1. Market Assessment and Forecast, By Country, 2016-2025 ($Million)
6.6.2. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.6.3. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.6.3.1. Brazil
6.6.3.1.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.6.3.1.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.6.3.2. Turkey
6.6.3.2.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.6.3.2.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.6.3.3. Saudi Arabia
6.6.3.3.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.6.3.3.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.6.3.4. South Africa
6.6.3.4.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.6.3.4.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.6.3.4.3. Market Assessment and Forecast, By End Users, 2016-2025 ($Million)
6.6.3.5. United Arab Emirates
6.6.3.5.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.6.3.5.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
6.6.3.6. Others
6.6.3.6.1. Market Assessment and Forecast, By Product Type, 2016-2025 ($Million)
6.6.3.6.2. Market Assessment and Forecast, By Disease Condition, 2016-2025 ($Million)
7. Company Profiles
7.1. Takeda Pharmaceutical Company Ltd.
7.1.1. Business Overview
7.1.2. Product Portfolio
7.1.3. Key Financials
7.1.4. Strategic Developments
7.2. Novartis
7.2.1. Business Overview
7.2.2. Product Portfolio
7.2.3. Key Financials
7.2.4. Strategic Developments
7.3. Savient Pharmaceuticals
7.3.1. Business Overview
7.3.2. Product Portfolio
7.3.3. Key Financials
7.3.4. Strategic Developments
7.4. Regeneron Pharmaceuticals
7.4.1. Business Overview
7.4.2. Product Portfolio
7.4.3. Key Financials
7.4.4. Strategic Developments
7.5. AstraZeneca plc
7.5.1. Business Overview
7.5.2. Product Portfolio
7.5.3. Key Financials
7.5.4. Strategic Developments
7.6. Horizon Pharma plc
7.6.1. Business Overview
7.6.2. Product Portfolio
7.6.3. Key Financials
7.6.4. Strategic Developments
7.7. BoehringerIngelheim
7.7.1. Business Overview
7.7.2. Product Portfolio
7.7.3. Key Financials
7.7.4. Strategic Developments
7.8. Merck & Co. Inc
7.8.1. Business Overview
7.8.2. Product Portfolio
7.8.3. Key Financials
7.8.4. Strategic Developments
7.9. Teijin Pharma Ltd
7.9.1. Business Overview
7.9.2. Product Portfolio
7.9.3. Key Financials
7.9.4. Strategic Developments
7.10. GlaxoSmithKline plc
7.10.1. Business Overview
7.10.2. Product Portfolio
7.10.3. Key Financials
7.10.4. Strategic Developments


Table of Figures

Table 1.Global Gout Therapeutics Market, By Product Type ($Million), 2016-2025
Table 3.NSAIDs Market, By Region ($Million), 2016-2025
Table 4.Corticosteroids Market, By Region ($Million), 2016-2025
Table 5.Colchicines Market, By Region ($Million), 2016-2025
Table 6.Urate-lowering Agents Market, By Region ($Million), 2016-2025
Table 10.Global Gout Therapeutics Market, By Disease Condition ($Million), 2016-2025
Table 11.Chronic Gout Market, By Region ($Million), 2016-2025
Table 12.Acute Gout Market, By Region ($Million), 2016-2025
Table 15.NorthAmerica Gout Therapeutics Market, By Country, 2016-2025 ($Million)
Table 16.North America Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 16.North America Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 17.U.S. Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 17.U.S. Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 18.Canada Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 18.Canada Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 19.Mexico Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 19.Mexico Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 20.Europe Gout Therapeutics Market, By Country, 2016-2025 ($Million)
Table 21.Europe Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 21.Europe Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 22.Germany Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 22.Germany Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 23.France Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 23.France Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 24.UK Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 24.UK Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 25.Italy Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 25.Italy Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 26.Spain Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 26.Spain Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 27.Russia Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 27.Russia Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 28.Rest of Europe Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 28.Rest of Europe Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 29.Asia-Pacific Diabetes Devices Market, By Country, 2016-2025 ($Million)
Table 30.Asia-Pacific Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 30.Asia-Pacific Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 31.Japan Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 31.Japan Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 32.China Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 32.China Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 33.Australia Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 33.Australia Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 34.India Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 34.India Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 35.South Korea Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 35.South Korea Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 36.Taiwan Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 35.Taiwan Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 37.Rest of Asia-Pacific Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 35.Rest of Asia-Pacific Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 38.Rest of the World Gout Therapeutics Market, By Country, 2016-2025 ($Million)
Table 30.Rest of the World Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 30.Rest of the World Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 40.Brazil Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 35.Brazil Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 41.Turkey Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 41.Turkey Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 42.Saudi Arabia Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 42.Saudi Arabia Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 43.South Africa Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 43.South Africa Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 44.United Arab Emirates Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 44.United Arab Emirates Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 45.Others Gout Therapeutics Market, By Product Type, 2016-2025 ($Million)
Table 44.Others Gout Therapeutics Market, By Disease Condition, 2016-2025 ($Million)
Table 46.Takeda Pharmaceutical Company Ltd.: Key Strategic Developments, 2015-2017
Table 47.Novartis: Key Strategic Developments, 2015-2017
Table 48.Becton, Dickinson and Company: Key Strategic Developments, 2015-2017
Table 49.Savient Pharmaceuticals: Key Strategic Developments, 2015-2017
Table 50.Regeneron Pharmaceuticals: Key Strategic Developments, 2015-2017
Table 51.AstraZeneca plc: Key Strategic Developments, 2015-2017
Table 52.Horizon Pharma plc: Key Strategic Developments, 2015-2017
Table 53.Boehringer Ingelheim: Key Strategic Developments, 2015-2017
Table 54.Teijin Pharma Ltd: Key Strategic Developments, 2015-2017
Table 55.GlaxoSmithKline plc: Key Strategic Developments, 2015-2017

Request Sample

* mark fields are compulsory